The $672M Power Play: How Cosette’s Acquisition of Mayne Pharma Signals a New Era in Women’s Health Investing
Women’s health is evolving and no longer a "niche play". Here’s what this multi-million dollar deal reveals about the future of M&A, private capital, and high-growth opportunities in the space.
Welcome to the latest issue of the Femmehealth Ventures Publication—your trusted source for insightful analysis of femtech innovations through an investor's lens, helping you identify the latest opportunities in women's health technology.
Keep reading with a 7-day free trial
Subscribe to FemmeHealth Ventures Alliance to keep reading this post and get 7 days of free access to the full post archives.